Press release
Retinitis Pigmentosa (RP) Market to Reach USD 1.65 Billion by 2034
Retinitis Pigmentosa
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71715
Although no universal cure currently exists, advances in gene therapy, retinal prosthetics (bionic eyes), stem cell therapy, and neuroprotective drugs are transforming the treatment outlook. Government recognition of RP as a rare disease, combined with orphan drug incentives and patient advocacy efforts, is fueling market expansion.
Market Overview
• Market Size (2024): USD 780 million
• Forecast (2034): USD 1.65 billion
• CAGR (2025-2034): 7.6%
The RP market is expanding rapidly, driven by gene therapy approvals, emerging retinal implants, and expanding clinical trials. Supportive care therapies like vitamin A supplementation and low-vision aids continue to play a role, but disease-modifying therapies are now entering the market.
Key Highlights:
• First gene therapy approval: Luxturna (voretigene neparvovec) for RPE65 mutation-associated retinal dystrophy.
• Strong innovation in stem cell-based regenerative medicine.
• Retinal implants offering functional vision restoration in advanced RP.
• Rising genetic testing adoption enabling early diagnosis.
Segmentation Analysis
By Product Type:
• Gene Therapies
o Luxturna (voretigene neparvovec)
o Pipeline therapies targeting multiple mutations (AAV-based, CRISPR)
• Retinal Prosthetics & Implants
o Argus II Retinal Prosthesis System
o Next-gen bionic eye technologies
• Pharmacological Therapies
o Neuroprotective Agents
o Vitamin A Palmitate & Antioxidants
o Emerging small molecules (e.g., ciliary neurotrophic factor - CNTF)
• Stem Cell Therapies
o Retinal progenitor cells
o iPSC-derived photoreceptors
• Supportive Care
o Low-vision aids
o Mobility training
By Platform:
• Gene Therapy
• Cell Therapy
• Medical Devices (implants, prosthetics)
• Small Molecules
By Technology:
• AAV and Lentiviral Vectors
• CRISPR-based Gene Editing
• Retinal Imaging & AI Diagnostics
• Bioelectronic Retinal Stimulation
By End Use:
• Hospitals
• Specialty Ophthalmology Clinics
• Research Institutes
• Home Care Settings
By Application:
• Autosomal Dominant RP
• Autosomal Recessive RP
• X-Linked RP
• Sporadic/Undifferentiated Cases
• Clinical Research
Segmentation Summary:
Gene therapy leads current innovation, while retinal implants and stem cell therapies represent high-growth areas. Hospitals and specialty clinics dominate the end-use segment, while research institutes remain key for trial activity.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71715/retinitis-pigmentosa-rp-market
Regional Analysis
North America
• Largest market with ~48% share in 2024.
• U.S. leads with FDA approval of Luxturna and strong retinal implant research.
• Advanced genetic testing adoption expanding patient identification.
Europe
• Accounts for ~29% share.
• Germany, UK, and France leading in gene therapy trials and ophthalmology research.
• EMA's rare disease support boosting innovation.
Asia-Pacific
• Fastest-growing region with CAGR of ~8.9%.
• Japan leading in stem cell therapy research (iPSC-based retinal regeneration).
• China and India expanding rare disease programs and clinical trial networks.
Middle East & Africa
• Smaller share due to limited rare disease infrastructure.
• Growth supported by partnerships with global NGOs and specialty ophthalmology hospitals.
Latin America
• Brazil and Mexico driving demand with expanding ophthalmology services.
• Gradual adoption of genetic testing and access to clinical trials.
Regional Summary:
North America and Europe dominate today due to strong R&D ecosystems, while Asia-Pacific will be the fastest-growing market, fueled by stem cell therapy innovation and increasing genetic testing.
Market Dynamics
Key Growth Drivers:
• Gene therapy breakthroughs like Luxturna opening new pathways.
• Increasing prevalence of inherited retinal disorders.
• Strong pipeline of gene editing and stem cell therapies.
• Expanding rare disease frameworks and orphan drug incentives.
Key Challenges:
• Extremely high cost of gene therapies (Luxturna ~USD 850,000).
• Limited patient eligibility due to mutation-specific therapies.
• Ethical and logistical hurdles in gene editing trials.
• Accessibility challenges in low- and middle-income regions.
Latest Trends:
• CRISPR-based gene editing trials for broader mutation coverage.
• AI-powered retinal imaging for early detection and monitoring.
• Advancements in bionic eyes offering partial vision restoration.
• Collaborations between biotech firms and patient advocacy groups.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71715
Competitor Analysis
Major Players in the Market:
• Novartis AG (Luxturna - commercialization)
• Spark Therapeutics (developer of Luxturna, Roche subsidiary)
• Second Sight Medical Products, Inc. (Argus II)
• MeiraGTx Holdings plc (gene therapy pipeline)
• Editas Medicine, Inc. (CRISPR-based therapies)
• BlueRock Therapeutics (stem cell-based therapies)
• AGTC (Applied Genetic Technologies Corporation)
• jCyte, Inc. (retinal progenitor cell therapy)
• Regenxbio Inc.
• Oxford Biomedica plc
Competitive Summary:
Novartis and Spark dominate with the first approved gene therapy, Luxturna. MeiraGTx, Editas, and AGTC are advancing next-generation gene therapies, while jCyte and BlueRock lead in stem cell treatments. Second Sight continues to pioneer retinal prosthetics. Competition is focused on gene editing, regenerative medicine, and bionic vision technologies.
Conclusion
The Retinitis Pigmentosa (RP) Market, valued at USD 780 million in 2024, is projected to reach USD 1.65 billion by 2034, growing at a CAGR of 7.6%. Advances in gene therapy, stem cell innovation, and retinal prosthetics are reshaping the future of RP management.
Key Takeaways:
• Luxturna set the precedent for mutation-specific gene therapies.
• Stem cell therapies and bionic eyes represent the next wave of innovation.
• North America and Europe dominate, but Asia-Pacific grows fastest.
• Patient advocacy, AI imaging, and orphan drug policies will accelerate adoption.
The next decade will redefine RP care, transitioning from supportive management to curative and vision-restoring therapies, creating strong opportunities for innovators, researchers, and healthcare providers.
This report is also available in the following languages : Japanese (網膜色素変性症(RP)市場), Korean (색소성 망막염(RP) 시장), Chinese (视网膜色素变性(RP)市场), French (Marché de la rétinite pigmentaire (RP)), German (Markt für Retinitis Pigmentosa (RP)), and Italian (Mercato della retinite pigmentosa (RP)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71715/retinitis-pigmentosa-rp-market#request-a-sample
Our More Reports:
Asia-Pacific Percutaneous Drainage Catheters Market
https://exactitudeconsultancy.com/reports/72342/asia-pacific-percutaneous-drainage-catheters-market
North America Percutaneous Drainage Catheters Market
https://exactitudeconsultancy.com/reports/72343/north-america-percutaneous-drainage-catheters-market
EU5 Percutaneous Drainage Catheters Market
https://exactitudeconsultancy.com/reports/72344/eu5-percutaneous-drainage-catheters-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinitis Pigmentosa (RP) Market to Reach USD 1.65 Billion by 2034 here
News-ID: 4177683 • Views: …
More Releases from Exactitude Consultancy
Prosthetic Joint Infection (PJI) Market to Reach USD 3.4 Billion by 2034
Prosthetic Joint Infection (PJI) is a severe complication that can occur after joint replacement surgeries, including hip, knee, shoulder, and other prosthetic implants. Although relatively rare (affecting 1-2% of patients), PJIs carry devastating consequences, often requiring revision surgery, long-term antibiotic therapy, and significant healthcare costs.
The global rise in orthopedic and joint replacement surgeries, driven by aging populations, obesity, and sports-related injuries, has increased the absolute number of PJI cases worldwide.…
Traveler's Diarrhea Market to Reach USD 1.6 Billion by 2034
Traveler's diarrhea (TD) is the most common illness affecting international travelers, typically caused by bacterial pathogens such as Escherichia coli (ETEC), Shigella, Campylobacter, and Salmonella, though viruses and parasites also contribute. It affects millions of travelers annually, especially in developing regions of Asia, Africa, and Latin America.
While TD is usually self-limiting, it can disrupt travel, cause severe dehydration, and lead to complications in vulnerable populations. The growing global travel industry,…
AIDS Dementia Market to Reach USD 2.7 Billion by 2034
AIDS dementia, also known as HIV-associated neurocognitive disorder (HAND) or HIV-associated dementia (HAD), is a neurological complication that occurs in advanced stages of HIV infection. Despite the global success of antiretroviral therapy (ART) in reducing HIV-related morbidity and mortality, cognitive decline remains a persistent challenge for many patients, particularly in low-resource settings.
The condition is caused by HIV's direct effects on the central nervous system (CNS) and compounded by opportunistic infections,…
Bacteremia Market to Reach USD 9.8 Billion by 2034
Bacteremia is a potentially life-threatening condition characterized by the presence of bacteria in the bloodstream, often resulting from infections such as pneumonia, urinary tract infections (UTIs), surgical site infections, or catheter-related infections. Left untreated, bacteremia can progress to sepsis, septic shock, and multi-organ failure.
The increasing prevalence of hospital-acquired infections (HAIs), coupled with the rise of multidrug-resistant (MDR) pathogens such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, has…
More Releases for Luxturna
Luxturna Industry Report 2025-2034: Market Dynamics, Drivers, And Forecasts
The Luxturna Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Luxturna Market Size During the Forecast Period?
In recent times, the market size for luxturna has seen a HCAGR of XX. The sector is projected to experience expansion from $XX million in…
Luxturna Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Eme …
What combination of drivers is leading to accelerated growth in the luxturna market?
The increase in genetic eye conditions is anticipated to boost the expansion of the luxturna market. Genetic eye disorders include a variety of inherited diseases brought on by gene mutations which impact the structure or function of the eyes, leading to vision problems like blindness or decreased vision. The escalating presence of these disorders is linked to a…
Gene Therapy Market Growth 2025-2032 | CRISPR Breakthroughs, Ophthalmic Advances …
The Future of the Gene Therapy Market | Key Developments, Investment Opportunities, and Market Growth Prospects
Breakthrough in Treating Childhood Blindness
Key Development:
Researchers at Great Ormond Street Hospital in London have achieved a major milestone by successfully treating children with Leber congenital amaurosis (LCA), a rare genetic disorder causing blindness.
Using minimally invasive keyhole surgeries, healthy copies of the AIPL1 gene were injected into the retina, restoring partial vision in four children aged…
Leading Growth Driver in the Luxturna Market in 2025: Growing Prevalence Of Gene …
What Is the Forecasted Market Size and Growth Rate for the Luxturna Market?
Over recent years, the Luxturna market size has seen a $XX surge. With a projected growth from $XX million in 2024, it is projected to rise to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. The growth during the historic period can be ascribed to factors like the rising instances of retinal diseases,…
Adeno Associated Virus Vectors In Gene Therapy Market to Grow Positively at a Pa …
DelveInsight's "Adeno Associated Virus Vectors In Gene Therapy - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Adeno Associated Virus Vectors In Gene Therapy market share of the individual therapies, current and forecasted Adeno Associated Virus Vectors In Gene Therapy market size from 2020 to 2034 segmented by seven major markets. The report also offers current Adeno Associated Virus Vectors In Gene Therapy…
Luxturna Gene Therapy Market Dynamics, Forecast, Analysis and Supply Demand 2020 …
Gene therapies have emerged as a promising treatment approach to address various diseases such as cancer, and certain inherited disorders with a single curative dosage. Although they are poised to ensure cost savings in the long run, their high initial expenses and uncertainties regarding their prolonged efficacy are an existing challenge for market players.
The Demand analysis of Gene Therapy Market offers a comprehensive analysis of diverse features, demand, product developments,…
